Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry

INTRODUCTION: Pirfenidone, an antifibrotic drug, slows-down the disease progression in idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of lung function and overall survival (OS) in real-world cohorts on longer follow-up exists. PATIENTS/METHODS: Of the enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurkova, Monika, Kriegova, Eva, Kolek, Vitezslav, Lostakova, Vladimira, Sterclova, Martina, Bartos, Vladimir, Doubkova, Martina, Binkova, Ilona, Svoboda, Michal, Strenkova, Jana, Janotova, Marketa, Plackova, Martina, Lacina, Ladislav, Rihak, Vladimir, Petrik, Frantisek, Lisa, Pavlina, Bittenglova, Radka, Tyl, Richard, Ondrejka, Gustav, Suldova, Hana, Lnenicka, Jaroslav, Psikalova, Jana, Snizek, Tomas, Homolka, Jiri, Kralova, Renata, Kervitzer, Jan, Vasakova, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341650/
https://www.ncbi.nlm.nih.gov/pubmed/30665416
http://dx.doi.org/10.1186/s12931-019-0977-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341650/
https://www.ncbi.nlm.nih.gov/pubmed/30665416
http://dx.doi.org/10.1186/s12931-019-0977-2

Ejemplares similares